Effectiveness of aspirin compare with heparin plus aspirin in recurrent pregnancy loss treatment: A Quasi experimental study

Nasrin Ghasemi1 M.D., Ph.D., Tahereh Jahaninejad1 M.Sc., Mahdia-sadat Mostafavi2 M.D., Abbas Aflatoonian2 M.D.

1. Department of Medical Genetics, Research and Clinical Center for Infertility, Shahid Sadooghi University of Medical Sciences, Yazd, Iran.
2. Department of Obstetrics and Gynecology, Research and Clinical Center for Infertility, Shahid Sadooghi University of Medical Sciences, Yazd, Iran.

Abstract
Background: Using aspirin, heparin, or both in women with unexplained recurrent miscarriage could be useful, because this problem might be initiated by thrombosis in decidual vessels.
Objective: To investigate the association between thrombophilia and unexplained recurrent miscarriage and to evaluate the efficacy of anticoagulant treatment.
Materials and Methods: In this quasi experimental, we enrolled 520 women, who had a history of recurrent miscarriage. Two hundred fifty two women with unexplained recurrent miscarriage were assigned to receive aspirin (80 mg daily) for two month before pregnancy and after confirmation of a viable pregnancy until 36 weeks of gestation or receive aspirin, as the same, plus heparin (5000 unit twice a day) subcutaneously after confirmation of viable pregnancy until 4 weeks after delivery. Type of medication was chosen for each woman according to number of abortion and age.
Results: Live-birth rates did not different significantly among the two study groups. The proportions of women who gave birth to a live normal infant were 74.5% in the group receiving aspirin plus heparin (combination-therapy group) and 79.8% in the aspirin group.
Conclusion: Live-birth rates did not different significantly among the two study groups. So, using aspirin or aspirin plus heparin did not change pregnancy rate in these patients. Using aspirin is easier than injecting heparin which should be chosen case by case.

Key words: Thrombophilia, Recurrent miscarriage, Anticoagulant, Live birth, Aspirin, Heparin.

Introduction

Recurrent pregnancy loss (RPL) is defined as two or more consecutive pregnancy losses before twenty week of gestation, which affects 1-3% of couples (1). In women with a history of recurrent miscarriage, the risk of miscarriage in a subsequent pregnancy is about 40-50%. It has a major influence on the wellbeing and psychosocial status of patients, therefore improved diagnosis and development of treatment strategies is essential (2, 3).

The risk of miscarriage is enhanced by variety of genetics and environmental factors. Genetic disorders, reproductive tract anatomical pathologies, infectious diseases, endocrine dysfunctions, autoimmune diseases, and thrombophilia are known to be the most important risk factors for RPL (4, 5). Thrombophilia or hypercoagulability is the propensity to develop thrombosis due to an abnormality in the coagulation system. Possible causes of thrombophilia can be either acquired or congenital (6).

Mutation in factor V, methylene tetra hydro folat reductase (MTHFR), the prothrombin or factor II genes, and protein C and S deficiency are the most frequent causes of congenital thrombophilia (7). Several observations have supported the correlation between congenital thrombophilia and recurrent fetal loss. Placental thrombosis and abruption has been found in women with recurrent miscarriage, which suffer from thrombophilia (8, 9). In addition, proinflammatory changes, altered
Th1 to Th2 cytokine ratio and complement activation, have been repeatedly found in these women (3). Normal pregnancies lead to haemostatic changes towards a procoagulatory state. This is followed by an increase concentration of clotting factors and fibrinogen and decrease level of anticoagulant factors with reduced fibrinolytic activity (10). It seems that some of RPL patients are in a permanent acquired procoagulatory state, which fibrin deposits are found in their intervillous space of the placentas (11).

The treatment mainly is aspirin and heparin. Aspirin is an anticoagulant that prevents thrombosis by the increase prostaglandin E2. It accelerates blood to placenta, which should be started from the beginning of pregnancy. Heparin has both anticoagulative and anti-inflammatory effects. Heparin does not penetrate the placenta and is harmless for fetus. It should be started at 6th week of gestation after confirmation of a viable pregnancy. Several studies have examined the use of these throughout pregnancy. They have demonstrated improved fetal outcomes, and also prevention of venous thromboembolism in mother during childbirth (12, 13). However, it was not confirmed by all previous study (14).

This study evaluated the effect of various anticoagulant treatments on the live-birth rate in women with a history of at least two unexplained miscarriages or thrombophilia. It tries to compare two methods of treatment, with aspirin and aspirin plus heparin.

**Materials and methods**

This quasi experimental study evaluated 520 women with recurrent pregnancy loss for four years, 2008-2012. They had referred to recurrent abortion clinic of Yazd Reproductive Sciences Institute. Two hundred and fifty two women out of 520 women were chosen, and they accepted to be part of this study by sign inform consent. These women divided to two groups. First group, 134 women, received aspirin (80mg daily) for at least two month before pregnancy and after confirmation of a viable pregnancy until 36 weeks of gestation. They were under 25 years old and had two abortions. Second group, 118 women, received aspirin the same as first group plus heparin (5000 unit twice a day) subcutaneously after confirmation of viable pregnancy until 4 weeks after delivery. They had more than two abortions and/or more than 25 years old.

Patients were explained about these medication complications and treatment was continued by their obstetrics in their pregnancy care unit. Their PTT was checked every month with heparin injections. Primary outcome was live-birth rate or pregnancy past 20 weeks. Secondary outcome was abortion. The Ethic Committee of Yazd Reproductive Sciences Institute confirmed this study. All women were followed during pregnancy to the end or were contacted by telephone every 3 months till the end of pregnancy.

**Statistical analysis**

The results analyzed by SPSS (version 15) and they were tested by chi-square test. The results were significant in p>0.05.

**Results**

The results showed that, 114 women from 134 get pregnant and completed their treatment with aspirin, and 102 women of 118 with aspirin plus heparin. From 36 out of 252, 25 women never used aspirin and/or heparin, which the pregnancy rate in this group was 60%. Eleven women with treatment never get pregnant even with assisted reproductive techniques. In the first group treated with aspirin, 89 had normal delivery or passed 20 weeks of gestation, 2 preterm labors with normal child and 23 miscarriages.

In second group treated with aspirin plus heparin, 73 had normal delivery or passed 20 weeks of gestation, 5 preterm labors with normal child and 24 miscarriages. From 25
women who get pregnant without any treatment, 10 had normal delivery. Pregnancy rate after treatment with aspirin compare with aspirin plus heparin was not significantly different (chi-square test, p>0.05).

Of 252 women referred to recurrent abortion clinic, 241 (95.6%) became pregnant, and 78.2% of those who became pregnant had a live birth. Live-birth rates were 79.8% with aspirin and 76.4% with aspirin plus heparin. The difference was not significant (p>0.05), but the success rate with aspirin was slightly higher than aspirin plus heparin. (Figure 1)

Table I. Successful pregnancy and abortion rate in RPL women after treatment with various anticoagulant agents

| Treatment                  | Normal delivery or passed 20 weeks | Preterm labor | Abortion | Sum | Percentage of success |
|----------------------------|-----------------------------------|---------------|----------|-----|-----------------------|
| Aspirin (N)                | 89                                | 2             | 23       | 114 | 79.8%                 |
| Aspirin + Heparin (N)      | 73                                | 5             | 24       | 102 | 76.4%                 |
| No medications (N)        | 10                                | 5             | 10       | 25  | 60%                   |

X² test.

Discussion

Present results showed that pregnancy rate with anticoagulant therapy could treat women with unexplained recurrent pregnancy loss, which results of using aspirin or heparin were nearly the same? The hypothesis that women with unexplained recurrent pregnancy loss might benefit from aspirin, heparin, or both was based on a presumption that this condition might be caused by thrombosis in decidual vessels (15, 16). However, antithrombotic therapy with heparin do not recommended for unexplained RPL in general. It is suggested for those with heritable thrombophilia, or with three or more losses, or second trimester losses that might benefit (17, 18).

Lauda et al found that levels of circulating procoagulant microparticles were higher in women with recurrent pregnancy loss than in control subjects (19). In Dolitzky et al study, 104 patients were randomized, 54 treated with enoxaparin and 50 with aspirin. Ninety four percent had successful pregnancy with enoxaparin and 81% with aspirin (12). They showed higher rate of success than present study, which could cause from patient selection. Also in a study aspirin or aspirin plus low molecular weight heparin were prescribed for 364 women with unexplained recurrent miscarriage, and live birth rates were not different significantly among two groups (20). In Tzafettas et al study success rate in two groups treated by aspirin or aspirin plus heparin were equal and was 92% (21).

Degiannidis et al found that low-molecular-weight heparin and low-dose aspirin daily during pregnancy appear to have a favorable effect on pregnancy outcome in selected women with RSAs and acquired or inherited thrombophilia (22). Discussion on the efficacy of aspirin and heparin progressed with recently published randomized-controlled trials (23). However, some study suggested anticoagulant therapy is not effective in idiopathic recurrent abortion treatment (13, 24).
Conclusion

In conclusion, present study did not find significant difference between the effectiveness of aspirin compare with aspirin and heparin in treatment of idiopathic recurrent abortion with unknown reason. As the success percentage of aspirin is higher and due to its consumption that is once a day orally and easily, it is more preferred to use only aspirin in comparison with the hypodermic treatment of heparin which is done twice a day. In the future, this is recommended to use aspirin and/or heparin according to the recurrent pregnancy loss characteristic, like number of abortion, age and so on.

Acknowledgments

Research Deputy of Yazd Shahid Sadoughi Medical Sciences University and Health Services gave all financial support for this project.

Conflict of interest

Authors have no conflict of interest in this project.

References

1. Toth B, Jeschke U, Rogenhofer N, Scholz C, Würfel W, Thaler CJ, et al. Recurrent miscarriage: current concepts in diagnosis and treatment. J Reprod Immunol 2010; 85: 25-32.
2. Carrington B, Sacks G, Regan L. Recurrent miscarriage: pathophysiology and outcome. Curr Opin Obstet Gynecol 2005; 17: 591-597.
3. Monien S, Kadecki O, Baumgarten S, Salama A, Dörner T, Kiesewetter H. Use of heparin in women with early and late miscarriages with and without thrombophilia. Clin Appl Thromb Hemost 2009; 15: 636-644.
4. Rai R, Regan L. Recurrent miscarriage. Lancet 2006; 368: 601-611.
5. Redline RW. Thrombophilia and placental pathology. Clin Obstet Gynecol 2006; 49: 885-894.
6. Heit JA. Thrombophilia: Common Questions on Laboratory Assessment and Management. Hematology Am Soc Hematol Educ Program 2007; 1: 127-135.
7. Behjati R, Modarressi MH, Jeddii-Tehrani M, Dokoohaki P, Ghasemi J, Zarnani AH, et al. Thrombophilic mutations in Iranian patients with infertility and recurrent spontaneous abortion. Ann Hematol 2006; 85: 268-271.
8. Silver RM, Warren JE. Preconception counseling for women with thrombophilia. Clin Obstet Gynecol 2006; 49: 906-919.
9. Mukhopadhay R, Saraswathy KN, Ghosh PK. MTHFR C677T and factor V Leiden in recurrent pregnancy loss: a study among an endogamous group in North India. Genet Test Mol Biomarkers 2009; 13: 861-865.
10. Brenner B. Haemostatic changes in pregnancy. Thromb Res 2004; 114: 409-414.
11. Rai R, Backos M, Baxter N, Chilcott I, Regan L. Recurrent miscarriage—a aspirin a day? Hum Reprod 2000; 15: 2220-2223.
12. Doltizky M, Inbal A, Segal Y, Weiss A, Brenner B, Carp H. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril 2006; 86: 362-366.
13. Milić G, Novakov Mikić A, Povazan L, Mitreski A, Kopitović V, Vejnović T. Thromboprophylaxis implementation during pregnancy in women with recurrent foetal losses and thrombophilia. Med Pregl 2011; 64: 471-475.
14. Kaandorp SP, Goddijn M, van der Post JA, Hutten BA, Verhoeye HR, Hamulyák K, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010; 362: 1586-1596.
15. Infante-Rivard C, David M, Gauthier R, Rivard GE. Lupus anticoagulants: anticolipid antibodies, and fetal loss a case-control study. N Engl J Med 1999; 325: 1063-1066.
16. Lockshin MD. Pregnancy loss in the antiphospholipid syndrome. Thromb Haemost 1999; 82: 641-648.
17. Greer IA. Antithrombotic treatment for recurrent pregnancy loss? J Thromb Haemost 2011; 9 (Suppl 1): 302-305.
18. Kaandorp S, DiNisio M, Goddijn M, Middeldorp S. Aspirin or anticoagulants for treating recurrent pregnancy loss in women without antiphospholipid syndrome. Cochrane Database Syst Rev 2009; (1): CD004734.
19. Laude I, Rongières-Bertrand C, Boyer-Neumann C, Wolf M, Mairovitz V, Hugel B, et al. Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb Haemost 2001; 85: 18-21.
20. Di Nisio M, Peters L, Middeldorp S. Aspirin or anticoagulants for treating. Cochrane Database Syst Rev 2005: CD004734.
21. Tzafettas J, Mamopoulos A, Anaipiotis A, Loufopoulos A, Psarra A, Klearchou N, et al. Thromboprophylaxis throughout pregnancy in women with previous history of recurrent miscarriages of unknown aetiology. Clin Exp Obstet Gynecol 2002; 29: 267-270.
22. Deligiannidis A, Parapanissiou E, Mavridis P, Tabakoudis G, Mavroudi A, Papastavrou T, et al. Thrombophilia and antithrombotic therapy in women with recurrent spontaneous abortions. J Reprod Med 2007; 52: 499-502.
23. McNamee K, Dawood F, Farquharson RG. Thrombophilia and early pregnancy loss. Best Pract Res Clin Obstet Gynaecol 2012; 26: 91-102.
24. Visser J, Ulander VM, Helmerhorst FM, Lampinen K, Morin-Papunen L, Bloemenkamp KW, et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. Thromb Haemost 2011; 105: 295-301.